---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-047679"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2021-09-13T23:59:59+00:00"
generated_at: "2026-06-29T04:06:47.005331+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma Announces Positive Phase 1b/2a Results for ATYR1923 in Pulmonary Sarcoidosis

## Summary
- ATYR1923 safe and well-tolerated with no drug-related serious adverse events in 37-patient pulmonary sarcoidosis trial.
- 5.0 mg/kg group achieved 58% steroid reduction from baseline and 33% of patients tapered completely off steroids.
- Absolute improvement in forced vital capacity (FVC) of 3.3% at week 24 in 5.0 mg/kg group vs placebo.
- Clinically meaningful improvements in dyspnea, cough, fatigue and King's Sarcoidosis scores in 5.0 mg/kg group.
- Company plans FDA end-of-Phase 2 meeting and expects to initiate registrational trial in 2022.

## SEC filing metadata
- accession: 0001564590-21-047679
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2021-09-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000156459021047679/0001564590-21-047679-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000156459021047679/life-8k_20210913.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-047679
- JSON: https://secwatch.observer/filing/0001564590-21-047679.json
- Plain text: https://secwatch.observer/filing/0001564590-21-047679.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.